We found evidence that CD8+ T cell and M1 cell inactivation were inhibited in the tumor microenvironment of ATRX-wt glioma patients with low risk scores; thus, we analyzed whether ICB therapy was beneficial for low-risk ATRX-wt glioma patients. Here, CD8A is linked to central nervous system cancer.